Article ; Online: Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab.
2021 Volume 57, Page(s) 80–85
Abstract: Background: Few data are available about real-life cardiotoxicity associated with s.c. versus i.v ... neither multiple events per patient were observed. A total of 184 patients received i.v. and 179 received ... s.c. trastuzumab. Compared with the s.c. formulation, a higher cardiotoxicity rate for the i.v ...
| Abstract | Background: Few data are available about real-life cardiotoxicity associated with s.c. versus i.v. trastuzumab treatment of early-stage, HER2-positive breast cancer, and little is known about its predisposing factors. Patients and methods: We retrospectively reviewed data of 363 adult patients treated with adjuvant trastuzumab for HER2-positive breast cancer. Univariate statistical analysis was performed, and a multivariable logistic model was developed to identify independent risk factors of cardiac toxicity. Results: Within 5 years, the overall incidence of events meeting our criteria was 11.8%, and an early discontinuation of trastuzumab was recorded in 20 patients (5.5%). No cases of congestive heart failure occurred, neither multiple events per patient were observed. A total of 184 patients received i.v. and 179 received s.c. trastuzumab. Compared with the s.c. formulation, a higher cardiotoxicity rate for the i.v. administration (15.2% vs 8.4%) was found, and particularly in those patients with cardiovascular risk factors (19.3% vs 8.7%), at the univariate and multivariate analyses. Although more patients with prior anthracycline-based chemotherapy experienced cardiac events, the association of this therapy with cardiac events was not significant. The incidence of cardiac events was not influenced by anthropometric data (e.g. body mass index) or a diagnosis of diabetes mellitus. 5-year event-free survival was 91.7% in the overall population; event-free survival rates were similar between the s.c. and the i.v. groups. Conclusion: Our study shows a more favorable safety profile of s.c. versus i.v trastuzumab administration. The use of s.c. trastuzumab could be advisable in at-risk patients. |
|---|---|
| MeSH term(s) | Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Breast Neoplasms/drug therapy ; Cardiotoxicity/epidemiology ; Chemotherapy, Adjuvant ; Female ; Heart/drug effects ; Humans ; Male ; Middle Aged ; Receptor, ErbB-2/analysis ; Retrospective Studies ; Trastuzumab/adverse effects ; Trastuzumab/therapeutic use ; Ventricular Function, Left/drug effects |
| Chemical Substances | Antibodies, Monoclonal ; Antineoplastic Agents ; ERBB2 protein, human (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1) ; Trastuzumab (P188ANX8CK) |
| Language | English |
| Publishing date | 2021-03-17 |
| Publishing country | Netherlands |
| Document type | Journal Article |
| ZDB-ID | 1143210-x |
| ISSN | 1532-3080 ; 0960-9776 |
| ISSN (online) | 1532-3080 |
| ISSN | 0960-9776 |
| DOI | 10.1016/j.breast.2021.03.004 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 3620: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
|||
| Zs.MO 588: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.